Compare Enveric Biosciences Inc (ENVB) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Royal Caribbean Cruises Ltd trades at $293.63 (market cap $78.36B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 14729.3× Enveric Biosciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.71% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RCL | |
|---|---|---|
Market Cap | $5.32M | $78.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $365.84 |
52-Week Low | $1.28 | $246.71 |
Enterprise Value | $408.82K | $99.64B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Royal Caribbean (RCL) trades at $289.26, up 2.18% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $328. The company demonstrates strong fundamentals with revenue growth from $16.5B in 2024 to $17.93B in 2025, net income margin of 24.36%, and robust cash flow from operations of $6.47B. Recent news highlights Caribbean demand offsetting European weakness and upcoming Q2 2026 earnings.
RCL presents a favorable investment case with solid profitability, earnings beats, and analyst optimism, though risks include high debt levels, economic sensitivity, and competitive pressures. The stock's current valuation below consensus target suggests potential upside, contingent on sustained travel demand and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
